Telehealth Monitoring in Inflammatory Bowel Disease: Effects on Medication Compliance, Self-Efficacy, and Quality of Life
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · May 7, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special program using telehealth—where patients receive care and support remotely—can help people with inflammatory bowel disease (IBD) stick to their medication, feel more confident in managing their health, and improve their overall quality of life. Participants will be randomly assigned to either a group that receives a structured telehealth program led by nurses for three months, which includes education, counseling, and regular check-ins, or to a control group that will only receive standard care and an educational booklet.
To join the study, participants should be at least 18 years old, have been diagnosed with IBD for at least six months, and be in a stable condition. They should also be able to read and write in Turkish and use a smartphone for video calls and messaging. The trial is currently recruiting participants, and those who take part will be evaluated before starting the program and again after 12 weeks to see how well the telehealth support worked.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals aged 18 years or older
- • Individuals aged 18 years or older
- • Able to read and write in Turkish
- • Diagnosed with inflammatory bowel disease (IBD) for at least 6 months
- • In clinical remission (Harvey-Bradshaw Index score \< 5 or Simple Clinical Colitis Activity Index score \< 3)
- • Able to use a smartphone
- • Have access to an online messaging application (e.g., WhatsApp) and a valid e-mail address
- • Capable of downloading and using a mobile or computer-based video conferencing application (e.g., Zoom)
- • Willing to participate in the study voluntarily
- Exclusion Criteria:
- • Diagnosed with any psychiatric or cognitive disorder
- • Having any condition that impairs communication
- • Pregnant women
- • Patients receiving infusion-based treatment
- • Having an advanced chronic disease
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Kimya Kılıçaslan, PhD Candidate
Principal Investigator
Istanbul University - Cerrahpasa Institute of Graudate Studies
Zeliha Tulek, PhD, Prof.
Study Director
Istanbul University - Cerrahpasa, Florence Nightingale Faculty of Nursing
Aykut Ferhat Çelik, MD, Prof.
Study Chair
Istanbul University - Cerrahpasa Cerrahpaşa Faculty of Medicine Department of Gastroenterology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported